These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18435965)

  • 41. [Repeated percutaneous transluminal septal myocardial ablation leads to reduction of left ventricular outflow-tract pressure gradient in hypertrophic obstructive cardiomyopathy: a case report].
    Takeda M; Mori T; Ohashi Y; Ichikawa S; Terashima M; Ejiri J; Awano K
    J Cardiol; 2006 Jun; 47(6):313-21. PubMed ID: 16800375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Usefulness of tissue Doppler imaging for demonstrating altered septal contraction sequence during dual-chamber pacing in obstructive hypertrophic cardiomyopathy.
    Ito T; Suwa M; Sakai Y; Hozumi T; Kitaura Y
    Am J Cardiol; 2005 Dec; 96(11):1558-62. PubMed ID: 16310440
    [TBL] [Abstract][Full Text] [Related]  

  • 43. One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response.
    Faber L; Welge D; Fassbender D; Schmidt HK; Horstkotte D; Seggewiss H
    Clin Res Cardiol; 2007 Dec; 96(12):864-73. PubMed ID: 17891518
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients.
    Faber L; Meissner A; Ziemssen P; Seggewiss H
    Heart; 2000 Mar; 83(3):326-31. PubMed ID: 10677415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristics of myocardial postsystolic shortening in patients with symptomatic hypertrophic obstructive cardiomyopathy before and half a year after alcohol septal ablation assessed by speckle tracking echocardiography.
    Yuan J; Chen S; Qiao S; Duan F; Zhang J; Wang H
    PLoS One; 2014; 9(6):e99014. PubMed ID: 24922531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis.
    van Dockum WG; Kuijer JP; Götte MJ; Ten Cate FJ; Ten Berg JM; Beek AM; Twisk JW; Marcus JT; Visser CA; van Rossum AC
    Eur Heart J; 2006 Dec; 27(23):2833-9. PubMed ID: 17098761
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy treated with percutaneous alcohol septal ablation: an echocardiographic study].
    Rivera S; Sitges M; Azqueta M; Marigliano A; Velamazán M; Miranda-Guardiola F; Betriu A; Paré C
    Rev Esp Cardiol; 2003 Dec; 56(12):1174-81. PubMed ID: 14670269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging.
    van Dockum WG; ten Cate FJ; ten Berg JM; Beek AM; Twisk JW; Vos J; Hofman MB; Visser CA; van Rossum AC
    J Am Coll Cardiol; 2004 Jan; 43(1):27-34. PubMed ID: 14715178
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ameliorating the severity of sleep-disordered breathing concomitant with heart failure status after percutaneous transluminal septal myocardial ablation for drug-refractory hypertrophic obstructive cardiomyopathy.
    Akita K; Maekawa Y; Kohno T; Tsuruta H; Murata M; Fukuda K
    Heart Vessels; 2017 Nov; 32(11):1320-1326. PubMed ID: 28555387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy; The Chinese experience in 119 patients from a single center.
    Li ZQ; Cheng TO; Zhang WW; Qiao SB; Zhao LY; Jin YZ; Guan RM; Liu L
    Int J Cardiol; 2004 Feb; 93(2-3):197-202. PubMed ID: 14975547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of alcohol-induced septal ablation on left atrial volume and ejection fraction assessed by real time three-dimensional transthoracic echocardiography in patients with hypertrophic cardiomyopathy.
    Hage FG; Karakus G; Luke WD; Suwanjutah T; Burri MV; Nanda NC; Aqel RA
    Echocardiography; 2008 Aug; 25(7):784-9. PubMed ID: 18754938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy.
    Knaapen P; Germans T; Camici PG; Rimoldi OE; ten Cate FJ; ten Berg JM; Dijkmans PA; Boellaard R; van Dockum WG; Götte MJ; Twisk JW; van Rossum AC; Lammertsma AA; Visser FC
    Am J Physiol Heart Circ Physiol; 2008 Feb; 294(2):H986-93. PubMed ID: 18156203
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography.
    Faber L; Seggewiss H; Gleichmann U
    Circulation; 1998 Dec; 98(22):2415-21. PubMed ID: 9832486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Percutaneous transluminal septal myocardial ablation in drug-resistant hypertrophic obstructive cardiomyopathy: 18-month follow-up results.
    Oomman A; Ramachandran P; Subramanyan K; Kalarickal MS; Osman MN
    J Invasive Cardiol; 2001 Jul; 13(7):526-30. PubMed ID: 11435640
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy.
    Nagueh SF; Lakkis NM; Middleton KJ; Killip D; Zoghbi WA; Quiñones MA; Spencer WH
    Circulation; 1999 Jan; 99(3):344-7. PubMed ID: 9918519
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-surgical myocardial reduction in hypertrophic obstructive cardiomyopathy.
    Mutlak D; Gruberg L; Reisner S; Markiewicz W
    Isr Med Assoc J; 2002 Feb; 4(2):86-90. PubMed ID: 11875998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Myocardial perfusion evaluation post percutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy by ⁹⁹Tc(m) MIBI SPECT MPI].
    Sun XX; Tian YQ; Qiao SB; Yuan JS; Duan FJ; Wang DY; Guo F; He ZX
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jun; 39(6):497-502. PubMed ID: 21924073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tissue Doppler imaging in hypertrophic cardiomyopathy: impact of intraventricular obstruction on longitudinal left ventricular function.
    Cardim N; Torres D; Morais H; Cândido A; Duarte R; Longo S; Ferreira T; Pereira A; Gouveia A; Reis RP; Correia JM
    Rev Port Cardiol; 2002 Mar; 21(3):271-97. PubMed ID: 12017801
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hemodynamic change in patients with hypertrophic obstructive cardiomyopathy before and after alcohol septal ablation using 4D flow magnetic resonance imaging: a retrospective observational study.
    Suwa K; Akita K; Iguchi K; Ushio T; Maekawa Y
    BMC Cardiovasc Disord; 2021 Apr; 21(1):198. PubMed ID: 33879058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Abnormal longitudinal myocardial functional reserve assessed by exercise tissue Doppler echocardiography in patients with hypertrophic cardiomyopathy.
    Ha JW; Ahn JA; Kim JM; Choi EY; Kang SM; Rim SJ; Jang Y; Shim WH; Cho SY; Oh JK; Chung N
    J Am Soc Echocardiogr; 2006 Nov; 19(11):1314-9. PubMed ID: 17098132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.